Korea Joongang Daily
Korea JoongAng Daily

Celltrion's biosimilar Yuflyma approved for sale in U.S.

Yuflyma, a Celltrion biosimilar of the autoimmune diseases drug Humira, was approved for sale in the United States.

2023-05-24

[ANALYSIS] Korean Humira biosimilars set for huge 2023

With Humira, the world’s top-selling drug for over a decade, losing its monopoly, Korean biosimilar makers are gearing up to tap into the approximately $20-billion market.

2023-02-19

Celltrion's CT-P17 biosimilar approved for use in Korea

Celltrion's CT-P17 biosimilar was approved for sale in Korea, the company said Friday.

2021-10-15